Covidien PLC (COV): Today's Featured Health Services Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Covidien ( COV) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day up 1.3%. By the end of trading, Covidien rose 61 cents (1.1%) to $58.21 on average volume. Throughout the day, 1.8 million shares of Covidien exchanged hands as compared to its average daily volume of 2.3 million shares. The stock ranged in a price between $57.63-$58.47 after having opened the day at $57.81 as compared to the previous trading day's close of $57.60. Other companies within the Health Services industry that increased today were: CombiMatrix Corporation ( CBMX), up 12.2%, Response Genetics ( RGDX), up 11.8%, Spherix ( SPEX), up 11.5%, and NeuroMetrix ( NUROD), up 8.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Covidien Public Limited Company develops, manufactures, and sells healthcare products for use in clinical and home settings in the United States and internationally. Covidien has a market cap of $27.17 billion and is part of the health care sector. The company has a P/E ratio of 14.6, below the S&P 500 P/E ratio of 17.7. Shares are up 27.5% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Covidien a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, solid stock price performance, reasonable valuation levels, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Theragenics Corporation ( TGX), down 5.2%, Celsion Corporation ( CLSN), down 4.5%, AdCare Health Systems ( ADK), down 3.4%, and IsoRay ( ISR), down 3.3%, were all laggards within the health services industry with Stryker Corporation ( SYK) being today's health services industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback